Tebentafusp elicits on-target cutaneous immune responses driven by cytotoxic T-cells in uveal melanoma patients.

Clicks: 50
ID: 281601
2025
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #69 of 74 articles by views in The Journal of clinical investigation

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Tebentafusp is the first T-cell receptor-based bispecific protein approved for clinical use in HLA-A*02:01+ adult patients with unresectable/metastatic uveal melanoma. It redirects T-cells toward gp100-expressing target cells, frequently inducing skin-related early adverse events. This study investigated immunological and cellular responses using single-cell and spatial analysis of skin biopsies from patients with metastatic uveal melanoma treated with tebentafusp. 81.8% of patients developed acute cutaneous adverse events, which correlated with improved survival. Multimodal analysis revealed a brisk infiltration of CD4+ and CD8+ T-cells, while melanocyte numbers declined. Single-cell RNA-sequencing revealed T-cell activation, proliferation, and IFN-γ/cytotoxic gene upregulation. CD8+ T-cells co-localized with melanocytes and upregulated LAG3, suggesting potential for combination therapies with tebentafusp. Melanocytes upregulated antigen presentation and apoptotic pathways, while pigmentation gene expression decreased. However, gp100 remained stably expressed. Sequential skin biopsies enable in vivo pharmacodynamic modeling of tebentafusp, offering insights into immune activation, toxicity, and treatment response. Examining the on-target effects of bispecifics in tissues amenable to longitudinal sampling enhances our understanding of toxicity and therapeutic escape mechanisms, guiding strategies for treatment optimization.
Reference Key
staeger2025tebentafusp Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Staeger, Ramon; Tastanova, Aizhan; Ghosh, Adhideb; Winkelbeiner, Nicola; Shukla, Prachi; Kolm, Isabel; Turko, Patrick; Benlahrech, Adel; Harper, Jane; Broomfield, Anna; Camera, Antonio; Ambrosio, Marianna; Haunerdinger, Veronika; Cheng, Phil F; Ramelyte, Egle; Pham, James P; Kreutmair, Stefanie; Becher, Burkhard; Levesque, Mitchell P; Dummer, Reinhard; Meier-Schiesser, Barbara
Journal The Journal of clinical investigation
Year 2025
DOI
10.1172/JCI181464
URL
Keywords
dermatology skin melanoma oncology cancer immunotherapy

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.